Synergy Pharma (SGYP) Tops Q4 EPS by 3c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Cipher Acquires Canadian Rights to TRULANCE from Synergy (SGYP) for $5M Upfront
February 28, 2018 7:07 AM ESTCipher Pharmaceuticals Inc. has acquired the exclusive Canadian rights to right to develop, market, distribute and sell TRULANCE from Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). TRULANCE is a once-daily tablet approved by the U.S. Food and Drug Administration ("FDA") for the treatment of adults with chronic idiopathic constipation ("CIC") and irritable bowel syndrome with constipation ("IBS-C").
"We are excited at the prospect of bringing an innovative new product to market that would be a safe and effective... More
